NCT01804712View on ClinicalTrials.gov

Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy

EARLY_PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2019

Conditions

Prostate Cancer

Interventions

DRUG

rituximab

Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).

Trial Locations (1)

92093-0698

Moores UCSD Cancer Center, La Jolla